About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
ResponsibilityBeing the largest Polish pharmaceutical company we want to help people to live a healthy life in a healthy world. Social responsibility is an integral part of the management strategy in our company.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
The first commercial series of the drug manufactured in the new Medana production department, belonging to the Polpharma Group, was released for trading. This way, the company completed a 4-year investment period, which included a new facility for the production of non-sterile liquid forms, a new warehouse of packaging materials and raw materials, and a new R&D laboratory, where development projects in the field of inhalation drugs are carried out.
According to the decision of the Supervisory Board of Polpharma S.A., the process of separating the Biotechnology Department from the Pharmaceutical Works Polpharma S.A. was completed. As a result, Polpharma Biologics became an independent legal entity.
Polpharma took first place in the XII Ranking of Responsible Companies – the most important list of leaders of social responsibility and sustainable development in Poland. For the first time in the history of the ranking, a Polish company has won the leadership position. Polpharma obtained the maximum possible number of points. The company would repeat this success in 2019.
A new investment was launched in Sieradz: construction of the new Non-Sterile Fluid Plant increased the production capacity of current drugs and enabled the introduction of further products from the portfolio of both Medana Pharma S.A. as well as other companies in Polpharma Group.
Polpharma celebrated its 80th anniversary. To mark this occasion, it organised the Polrun relay race.
Polpharma published the first CSR report according to the Global Reporting Initiative (GRI) guidelines.
Polpharma started a strategic joint venture cooperation in the area of biotechnology with the German company Neuraxpharm.
The company Sanfarm, based in the Tarnobrzeg Special Economic Zone, became part of Polpharma S.A. Pharmaceutical Works. Following the merger of the two companies, Polpharma’s Manufacturing Division in Nowa Dęba was established to carry out pharmaceutical manufacturing operations for both member companies of Polpharma Group and third parties.
Polpharma passed an inspection by the Food and Drug Administration (FDA). As a result, APIs manufactured by the company gained access to the highly developed US market.
Polpharma received ISO 14001 environmental certificate and an OHSAS 18001 occupational health and safety certificate.
Polpharma began strategic cooperation with Akrikhin – one of the largest pharmaceutical companies in Russia.
Polpharma established an independent affiliated company in Belarus. Previously, the division in Lithuania was responsible for this country.
Polpharma opened a new training and administration centre in Starogard Gdański, which significantly expanded the company’s capabilities relating to the organisation of training sessions and meetings with clients and guests.
The company started operation of a new ampoule production facility. Its annual production capacity amounts to 50 million glass ampoules. The property was designed and built in accordance with cGMP requirements for sterile production.
The company opened another facility – a Logistics Centre. The building complies with the requirements of Good Distribution Practice (GDP) for the storage of pharmaceutical products.
Polpharma opened a modern building for the Research and Development Centre and Quality Control Laboratory. The facility meets the requirements of Good Laboratory Practice (GLP). It is one of the largest facilities of its kind in Central and Eastern Europe.
Polpharma implemented a coherent and modern visual identification for packages of prescription drugs.
Polscreen, a National Coronary Heart Disease Prevention Program, began. It was the largest global population-based study, developed by the Prevention Committee of the Polish Cardiac Society, financed by a research grant for Polpharma and awarded funds for the years 2002–2005.
A Trade Office was established in Warsaw, with dynamic and modern marketing and sales structures. The Office is located at ul. Sapieżyńska.
The first Etopiryna commercial appeared on TV. Since that time, this drug for headache has inevitably been associated with Ms Goździkowa, a well-known commercial actress.
Polpharma established the Foundation for the Development of Polish Pharmacy and Medicine, which annually announces a competition for the best research projects.
The company opened a division in Moscow operating in the Russian Federation and the Central Asian republics. It also established a branch in Ukraine.
A new chapter in Polpharma history opened on 20 July. The company became a privately-owned entity, with all its shares held by Polish investors. The Spectra Management and Prokom Investments Consortium became the majority shareholder of the Company. This was the beginning of restructuring and significant investment in the development of the company.
Polpharma began the construction of a new solid dosage forms manufacturing facility. The facility, built through the cooperation of an international team, was one of the most modern pharmaceutical plants in Europe.
The company starts business operation as a sole-shareholder company owned by the State Treasury, and returns to the historic name “Polpharma”.
The company exceeded 3000 employees. Exports of pharmaceutical substances and medicines represented approximately 50% of the company’s sales. The products of Starogard-based “Polfa” were sold to 60 countries on all continents.
The production of pharmaceutical substances grew, followed by the production of finished dosage forms: tablets and ampoules.
Polpharma was nationalised. Two chemists – Zygmunt Gmaj and Jerzy Sumczyński – become the managers of the facility.
